FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4284897982> ?p ?o ?g. }

• W4284897982 endingPage "e004668" @default.
• W4284897982 startingPage "e004668" @default.
• W4284897982 abstract "Background Acral melanoma is a rare melanoma subtype with poor prognosis. Importantly, these patients were not identified as a specific subgroup in the landmark melanoma trials involving ipilimumab and the anti-programmed cell death protein-1 (PD-1) agents nivolumab and pembrolizumab. There is therefore an absence of prospective clinical trial evidence regarding the efficacy of checkpoint inhibitors (CPIs) in this population. Acral melanoma has lower tumor mutation burden (TMB) than other cutaneous sites, and primary site is associated with differences in TMB. However the impact of this on the effectiveness of immune CPIs is unknown. We examined the efficacy of CPIs in acral melanoma, including by primary site. Methods Patients with unresectable stage III/IV acral melanoma treated with CPI (anti-PD-1 and/or ipilimumab) were studied. Multivariable logistic and Cox regression analyses were conducted. Primary outcome was objective response rate (ORR); secondary outcomes were progression-free survival (PFS) and overall survival (OS). Results In total, 325 patients were included: 234 (72%) plantar, 69 (21%) subungual and 22 (7%) palmar primary sites. First CPI included: 184 (57%) anti-PD-1, 59 (18%) anti-PD-1/ipilimumab combination and 82 (25%) ipilimumab. ORR was significantly higher with initial anti-PD-1/ipilimumab compared with anti-PD-1 (43% vs 26%, HR 2.14, p=0.0004) and significantly lower with ipilimumab (15% vs 26%, HR 0.49, p=0.0016). Landmark PFS at 1 year was highest for anti-PD-1/ipilimumab at 34% (95% CI 24% to 49%), compared with 26% (95% CI 20% to 33%) with anti-PD-1 and 10% (95% CI 5% to 19%) with ipilimumab. Despite a trend for increased PFS, anti-PD-1/ipilimumab combination did not significantly improve PFS (HR 0.85, p=0.35) or OS over anti-PD-1 (HR 1.30, p=0.16), potentially due to subsequent therapies and high rates of acquired resistance. No outcome differences were found between primary sites. Conclusion While the ORR to anti-PD-1/ipilimumab was significantly higher than anti-PD-1 and PFS numerically higher, in this retrospective cohort this benefit did not translate to improved OS. Future trials should specifically include patients with acral melanoma, to help determine the optimal management of this important melanoma subtype." @default.
• W4284897982 created "2022-07-09" @default.
• W4284897982 creator A5004690917 @default.
• W4284897982 creator A5008364803 @default.
• W4284897982 creator A5008479799 @default.
• W4284897982 creator A5008736570 @default.
• W4284897982 creator A5009024807 @default.
• W4284897982 creator A5009968141 @default.
• W4284897982 creator A5012803590 @default.
• W4284897982 creator A5013521399 @default.
• W4284897982 creator A5018372804 @default.
• W4284897982 creator A5020064368 @default.
• W4284897982 creator A5022293880 @default.
• W4284897982 creator A5022503555 @default.
• W4284897982 creator A5022520811 @default.
• W4284897982 creator A5023542650 @default.
• W4284897982 creator A5025067315 @default.
• W4284897982 creator A5025478490 @default.
• W4284897982 creator A5026158961 @default.
• W4284897982 creator A5028592995 @default.
• W4284897982 creator A5031315234 @default.
• W4284897982 creator A5032620018 @default.
• W4284897982 creator A5034014576 @default.
• W4284897982 creator A5036987287 @default.
• W4284897982 creator A5038584242 @default.
• W4284897982 creator A5039730061 @default.
• W4284897982 creator A5040291209 @default.
• W4284897982 creator A5048111860 @default.
• W4284897982 creator A5048419838 @default.
• W4284897982 creator A5049720337 @default.
• W4284897982 creator A5052403208 @default.
• W4284897982 creator A5056132643 @default.
• W4284897982 creator A5062851041 @default.
• W4284897982 creator A5064923908 @default.
• W4284897982 creator A5065819179 @default.
• W4284897982 creator A5066472402 @default.
• W4284897982 creator A5066969407 @default.
• W4284897982 creator A5069095893 @default.
• W4284897982 creator A5070576000 @default.
• W4284897982 creator A5079560617 @default.
• W4284897982 creator A5082278497 @default.
• W4284897982 creator A5082449165 @default.
• W4284897982 creator A5083026922 @default.
• W4284897982 creator A5083061830 @default.
• W4284897982 creator A5083431383 @default.
• W4284897982 creator A5088390068 @default.
• W4284897982 creator A5089522747 @default.
• W4284897982 creator A5090080848 @default.
• W4284897982 creator A5090545021 @default.
• W4284897982 date "2022-07-01" @default.
• W4284897982 modified "2023-10-17" @default.
• W4284897982 title "Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma" @default.
• W4284897982 cites W2096223992 @default.
• W4284897982 cites W2103152130 @default.
• W4284897982 cites W2161890731 @default.
• W4284897982 cites W2171202246 @default.
• W4284897982 cites W2408787182 @default.
• W4284897982 cites W2519469881 @default.
• W4284897982 cites W2553340100 @default.
• W4284897982 cites W2568245861 @default.
• W4284897982 cites W2605093443 @default.
• W4284897982 cites W2611187032 @default.
• W4284897982 cites W2611270905 @default.
• W4284897982 cites W2621161007 @default.
• W4284897982 cites W2753432434 @default.
• W4284897982 cites W2806962208 @default.
• W4284897982 cites W2900925644 @default.
• W4284897982 cites W2901290714 @default.
• W4284897982 cites W2910094874 @default.
• W4284897982 cites W2968595910 @default.
• W4284897982 cites W2983195778 @default.
• W4284897982 cites W2999304916 @default.
• W4284897982 cites W3013199660 @default.
• W4284897982 cites W3014701396 @default.
• W4284897982 cites W3033948992 @default.
• W4284897982 cites W3043703771 @default.
• W4284897982 cites W3045360487 @default.
• W4284897982 cites W3092852290 @default.
• W4284897982 cites W3109060575 @default.
• W4284897982 cites W3134351487 @default.
• W4284897982 cites W3166578944 @default.
• W4284897982 cites W3171006409 @default.
• W4284897982 cites W3193549844 @default.
• W4284897982 cites W3197265554 @default.
• W4284897982 cites W4225984187 @default.
• W4284897982 doi "https://doi.org/10.1136/jitc-2022-004668" @default.
• W4284897982 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35793872" @default.
• W4284897982 hasPublicationYear "2022" @default.
• W4284897982 type Work @default.
• W4284897982 citedByCount "11" @default.
• W4284897982 countsByYear W42848979822022 @default.
• W4284897982 countsByYear W42848979822023 @default.
• W4284897982 crossrefType "journal-article" @default.
• W4284897982 hasAuthorship W4284897982A5004690917 @default.
• W4284897982 hasAuthorship W4284897982A5008364803 @default.
• W4284897982 hasAuthorship W4284897982A5008479799 @default.
• W4284897982 hasAuthorship W4284897982A5008736570 @default.
• W4284897982 hasAuthorship W4284897982A5009024807 @default.

• next